Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Catalyst Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 16 years, with the latest figure at $122.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.24% year-over-year to $122.3 million; the TTM value through Dec 2025 reached $122.3 million, up 3.24%, while the annual FY2025 figure was $122.3 million, 3.24% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $122.3 million in Q4 2025 per CPRX's latest filing, roughly flat from $122.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $122.3 million in Q4 2025 to a low of $102.8 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $110.4 million, with a median of $106.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): fell 0.99% in 2022, then grew 11.46% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $103.4 million in 2021, then decreased by 0.0% to $103.4 million in 2022, then increased by 2.81% to $106.3 million in 2023, then increased by 11.46% to $118.5 million in 2024, then grew by 3.24% to $122.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Shares Outstanding (Weighted Average) are $122.3 million (Q4 2025), $122.1 million (Q3 2025), and $122.2 million (Q2 2025).